The present study therefore aims to investigate the possible predictive implications of this SNP in the IL-32 gene on the severity of the disease and the clinical response to TNFI’s (including adalimumab or etanercept) in RA patients. The gene discussed is IL32; the disease is rheumatoid arthritis.